Latest Conference Articles

February 26th 2017, 12:11am

Transplantation and Cellular Therapy Meetings

Bart Scott, MD, Fred Hutchinson Cancer Research Center, explains the importance of the intensity of conditioning for stem cell transplants.

February 25th 2017, 8:01pm

Transplantation and Cellular Therapy Meetings

Robert Korngold, PhD, John Theurer Cancer Center looks back on the advances we've made so far in bone marrow transplant.

February 25th 2017, 11:34am

Transplantation and Cellular Therapy Meetings

Treatment with an inactivated varicella zoster virus vaccine, known as V212, lowered the cumulative incidence rate of herpes zoster infection and complications for patients undergoing autologous hematopoietic stem cell transplantation.

February 25th 2017, 5:03am

Transplantation and Cellular Therapy Meetings

Rates of early relapse post-autologous stem cell transplant in patients with relapsing multiple myeloma have not changed over time, but post-relapse survival among early relapsers has improved for patients transplanted after 2005 and for those relapsing since 2008.

February 25th 2017, 4:14am

Transplantation and Cellular Therapy Meetings

Dr. Lancet of Moffitt Cancer Center explains the use of CPX-351 treatment compared to induction chemotherapy, for older adult patients with acute myeloid leukemia.

February 25th 2017, 2:37am

Transplantation and Cellular Therapy Meetings

Partow Kebriaei, MD, discusses the Iomab-B clinical trial for older patients with acute myeloid leukemia.

February 25th 2017, 1:17am

Transplantation and Cellular Therapy Meetings

According to data from a phase I/II clinical trial, carfilzomib can be safely combined with melphalan in a conditioning regimen prior to autologous hematopoietic cell transplantation in patients with relapsed multiple myeloma.

February 23rd 2017, 10:48pm

Transplantation and Cellular Therapy Meetings

More patients with acute myeloid leukemia could proceed to transplant following treatment with CPX-351 compared with the traditional 7+3 chemotherapy regimen.

February 21st 2017, 3:02am

Genitourinary Cancers Symposium (ASCO GU)

At the 2017 Genitourinary Cancers Symposium, Nicholas J. Vogelzang, MD, discussed diagnostic practices and emerging therapies in the field of bladder cancer.

February 21st 2017, 1:29am

Genitourinary Cancers Symposium (ASCO GU)

The combination of cabozantinib and nivolumab, with or without ipilimumab, proved safe and active in advanced genitourinary cancers, particularly urothelial cancer.

February 21st 2017, 1:12am

Genitourinary Cancers Symposium (ASCO GU)

Patients with PD-L1-positive metastatic renal cell carcinoma had a reduction in the risk of progression or death when treated in frontline with the combination of atezolizumab and bevacizumab instead of sunitinib, according to results of a randomized trial.

February 20th 2017, 11:45pm

Genitourinary Cancers Symposium (ASCO GU)

Fred Saad, MD, professor and chairman of Urology, director of Genitourinary Oncology, the University of Montreal Hospital Centers, discusses recent updates in active surveillance for patients with prostate cancer.

February 20th 2017, 8:37pm

Genitourinary Cancers Symposium (ASCO GU)

Thomas Powles, MD, Barts Cancer Institute, discusses durvalumab as a second-line therapy in locally advanced and metastatic urothelial cancer.

February 19th 2017, 4:18am

Genitourinary Cancers Symposium (ASCO GU)

Five of 8 patients with metastatic urothelial cancer benefited from the combination of ipilimumab and nivolumab after having no response to single-agent nivolumab.

February 19th 2017, 3:46am

Genitourinary Cancers Symposium (ASCO GU)

Combining the PD-1 inhibitor pembrolizumab with chemotherapy induced objective responses in one-third of patients with previously treated metastatic urothelial carcinoma.

February 18th 2017, 10:44pm

Genitourinary Cancers Symposium (ASCO GU)

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the promise of immuno-oncology agents in sarcomatoid renal cell carinoma (RCC).

February 18th 2017, 10:40pm

Genitourinary Cancers Symposium (ASCO GU)

Gary Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the immune response results of vesigenurtacel-I (HS-410) vaccine in non-muscle invasive bladder cancer (NMIBC).

February 18th 2017, 10:36pm

Genitourinary Cancers Symposium (ASCO GU)

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses bone biomarkers for radium-223 dichloride (Xofigo) in castration-resistant prostate cancer.

February 18th 2017, 8:29am

Genitourinary Cancers Symposium (ASCO GU)

The PD-L1 inhibitor durvalumab demonstrated compelling clinical activity and a manageable safety profile as second-line therapy for locally advanced or metastatic urothelial cancer.

February 18th 2017, 7:10am

Genitourinary Cancers Symposium (ASCO GU)

The genomic-based Decipher test effectively predicted metastasis and prostate cancer-specific mortality from diagnostic biopsy specimens for patients with intermediate- and high-risk prostate cancer.